Allergy Therapeutics (LON:AGY) Shares Down 13.7% – What’s Next?

Allergy Therapeutics plc (LON:AGY – Get Free Report) shares dropped 13.7% on Thursday. The stock traded as low as GBX 1.21 and last traded at GBX 1.21. 8,691,818 shares were traded during trading, an increase of 1,548% from the average session volume of 527,447 shares. The stock had previously closed at GBX 1.40.

Allergy Therapeutics Stock Performance

The firm has a fifty day moving average of GBX 3.88 and a 200-day moving average of GBX 7.44. The company has a quick ratio of 1.48, a current ratio of 2.29 and a debt-to-equity ratio of -646.31. The stock has a market capitalization of £76.50 million, a price-to-earnings ratio of -1.25, a PEG ratio of -30.70 and a beta of 0.83.

Allergy Therapeutics Company Profile

(Get Free Report)

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.

See Also

Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.